Clinical and laboratory Efects of vitamin D supplementation in adolescent with polycystic ovarian syndrome and vitamin D deficiency

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016021125732N2

Enrollment

Registered

2016-05-01

Start date

2016-01-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adolescent with polycystic ovarian syndrome and vitamin D deficiency. Polycystic ovarian syndrome

Interventions

Intervention 1: In the intervention group, 50 000 IU of vitamin D weekly for 8 weeks will be given. PCOS symptoms, patients should not interfere with effective drugs such as oral contraceptives COCS,

Prevention

In the intervention group, 50 000 IU of vitamin D weekly for 8 weeks will be given. PCOS symptoms, patients should not interfere with effective drugs such as oral contraceptives COCS, metformin, medr

The control group, placebo will be given for 8 weeks. PCOS symptoms, patients should not interfere with effective drugs such as oral contraceptives COCS, metformin, medroxyprogesterone and so on. The

Eligibility

Sex/Gender

Female

Age

80 Years to 76 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age 14 to 18 years old; people with impaired ovulation or anovulation for oligoovulation (oligo- and / or anovulation); 2 and 3 Hyperandrogenemia clinical hyperandrogenism or There polycystic ovarian morphology on ultrasound and they are deficient in vitamin D, and the study Azargoon et al(1) known as polycystic ovarian syndrome. Exclusion criteria: people who do not have full consent to participate in this study; Those who did not use vitamin D to regular weekly; Those in the intervention of the symptoms of polycystic ovary syndrome drugs such as birth control pills, metformin, medroxyprogesterone and progesterone intramuscular injection except in the event of amenorrhea has 45 days from the previous cycle dose of 200 mg for the induction periods are used.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Measuring vitamin D. Timepoint: Started. Method of measurement: Laboratory - using the kit for measuring vitamin D, with EUROIMMUN, the UK.	—

Secondary

Measure	Time frame
Ultrasonography. Timepoint: In 3 to 5 days of menstrual bleeding. Method of measurement: Abdominal Ultrasonography, by one sonographer.;Measuring vitamin D. Timepoint: After the intervention. Method of measurement: Laboratory - using the kit for measuring vitamin D, with EUROIMMUN, the UK.;Blood pressure measurement. Timepoint: After the intervention. Method of measurement: Manometer using a pan with 710 made in Taiwan, the left arm in a sitting position.;Measure weight. Timepoint: After the intervention. Method of measurement: Scales with 100 g.;Measuring stature. Timepoint: After the intervention. Method of measurement: Using tape measure with an accuracy of one centimeter.	—

Measure

Time frame

Ultrasonography. Timepoint: In 3 to 5 days of menstrual bleeding. Method of measurement: Abdominal Ultrasonography, by one sonographer.;Measuring vitamin D. Timepoint: After the intervention. Method of measurement: Laboratory - using the kit for measuring vitamin D, with EUROIMMUN, the UK.;Blood pressure measurement. Timepoint: After the intervention. Method of measurement: Manometer using a pan with 710 made in Taiwan, the left arm in a sitting position.;Measure weight. Timepoint: After the intervention. Method of measurement: Scales with 100 g.;Measuring stature. Timepoint: After the intervention. Method of measurement: Using tape measure with an accuracy of one centimeter.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mojgan Rahmanian

Semnan University of Medical Sciences, Vice Chancellor for Research, Semnan

are20935@gmail.com+98 23 3345 1336

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026